Specify a stock or a cryptocurrency in the search bar to get a summary
Intervacc AB
IVACCIntervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden. Address: Västertorpsvägen 135, Hägersten, Sweden, 129 44
Analytics
WallStreet Target Price
82.42 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IVACC
Dividend Analytics IVACC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IVACC
Stock Valuation IVACC
Financials IVACC
Results | 2019 | Dynamics |